Article · 20 May 2025
OtherPublished 26 Jul 2016
Tigecycline: an overview and update
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tigecycline is the first novel broad-spectrum glycylcycline antimicrobial agent. This agent has been shown to have broad spectrum in vitro activity against Gram-positive and -negative bacteria, atypical pathogens, anaerobic bacteria and organisms that have become resistant to other antimicrobial agents. Specifically, tigecycline is active against: Escherichia coli – including extended spectrum b-lactamase producing strains; Staphylococcus aureus – including methicillin-resistant strains; Enterococcus – including vancomycinresistant strains; and Streptococcus pneumoniae – including penicillin-resistant strains and tetracyclineresistant strains in vitro. Characteristics of the drug include: it is bacteriostatic, it is given via intravenous administration and twice-daily dosing, it has a post-antibiotic effect and good tissue penetration, and no dosage adjustment for renal or hepatic impairment is needed. Tigecycline has been shown to be efficacious for treatment of complicated skin and soft-tissue infections, for complicated intra-abdominal infections and, more recently, has been approved in Canada for the treatment of community-acquired pneumonia requiring hospitalization. Additionally, this drug has a safety profile comparable with other agents and classes of antimicrobial agents. The most common side effects reported from clinical trials with tigecycline include nausea (24.4%), vomiting (19.2%) and diarrhea (13.8%), and these values are similar or more frequent than that seen with comparator agents.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Joseph M Blondeau”
